FoRx Therapeutics AG, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, closed a USD 50m Series A Financing Round with existing investors including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures (Merck). The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.

VISCHER advises FoRx Therapeutics since its incorporation. The team includes Christian Wyss (Partner, Corporate/M&A and Life Sciences), Timothy Woodtli (Senior Associate, Corporate/M&A and Life Sciences) and Natacha Tang (Associate, Corporate/M&A and Life Sciences).

Author: Timothy Woodtli